Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $36,000.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $9.37 on Monday. The company has a 50-day moving average of $8.83 and a two-hundred day moving average of $9.15. Theravance Biopharma, Inc. has a 12-month low of $8.13 and a 12-month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $14.54 million. Theravance Biopharma had a negative net margin of 72.79% and a negative return on equity of 18.97%. On average, equities research analysts expect that Theravance Biopharma, Inc. will post -0.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TBPH. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, May 29th. StockNews.com upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, BTIG Research assumed coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 target price for the company.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. China Universal Asset Management Co. Ltd. grew its holdings in shares of Theravance Biopharma by 324.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 4,402 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 2,227 shares in the last quarter. Gerber LLC purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth about $112,000. Simplicity Solutions LLC purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth about $141,000. Finally, Bleakley Financial Group LLC purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth about $141,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.